Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: a new personalized medical approach
- PMID: 25035274
- PMCID: PMC4123392
- DOI: 10.2215/CJN.05880614
Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: a new personalized medical approach
Keywords: anti-PLA2R antibodies; glomerulonephritis; membranous GN.
Comment on
-
Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1386-92. doi: 10.2215/CJN.10471013. Epub 2014 Jul 17. Clin J Am Soc Nephrol. 2014. PMID: 25035272 Free PMC article.
References
-
- Euroimmun US: FDA allows marketing of first non-invasive test to help in identifying cause of certain kidney disease. May 29, 2014. Available at http://www.euroimmun.us/fda-released/new-fda-release-pla2r-ifa US Food and Drug Administration http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K132195 Both Accessed June 27, 2014
-
- Dähnrich C, Komorowski L, Probst C, Seitz-Polski B, Esnault V, Wetzels JF, Hofstra JM, Hoxha E, Stahl RA, Lambeau G, Stöcker W, Schlumberger W: Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta 421: 213–218, 2013 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
